Skip to main content

New! You can personalise your feed. Try it now

Advertisement

Advertisement

Covid-19 vaccines ‘sufficiently’ effective and safe; Govt to provide financial support if recipients suffer adverse side-effects

SINGAPORE — Covid-19 vaccines will be approved in Singapore against the disease only if they are “sufficiently efficacious and safe for use” and only if the benefits outweigh the risks of adverse side-effects, Health Minister Gan Kim Yong told Parliament on Monday (Jan 4).

Responding to questions from Members of Parliament on vaccine safety, Health Minister Gan Kim Yong gave the assurance that they are sufficiently effective and safe for use against Covid-19.

Responding to questions from Members of Parliament on vaccine safety, Health Minister Gan Kim Yong gave the assurance that they are sufficiently effective and safe for use against Covid-19.

Follow TODAY on WhatsApp

  • Health Minister Gan Kim Yong gave the assurance that the Pfizer-BioNTech vaccines for Covid-19 are sufficiently effective and safe for use
  • The Ministry of Health will roll out a vaccine injury financial assistance programme for recipients who suffer adverse side-effects
  • Few are expected to need this, but the scheme will give people peace of mind
  • MOH will formally study the effects of a new, more infectious UK strain on vaccines

 

SINGAPORE — Covid-19 vaccines will be approved in Singapore against the disease only if they are “sufficiently efficacious and safe for use” and only if the benefits outweigh the risks of adverse side-effects, Health Minister Gan Kim Yong told Parliament on Monday (Jan 4).

And if people suffer from a serious adverse reaction due to the vaccines, the Government will provide financial assistance via a vaccine injury financial assistance programme to support them.

“While we expect few to need this, the programme will give peace of mind to those taking the vaccination,” he said.

More information on the programme will be announced later.

Mr Gan said that the common side-effects of the Pfizer-BioNTech vaccine, which is the only one approved for use in Singapore so far, are similar to those for other established vaccines and usually resolve on their own.

He was responding to several questions from Members of Parliament (MPs) on the safety, efficacy and side-effects of the vaccines.

For instance, Workers’ Party chairman Sylvia Lim, an MP for Aljunied Group Representation Constituency, had asked Mr Gan about the criteria and benchmarks used by the Health Sciences Authority (HSA) when it evaluates the vaccines.

In response, Mr Gan said that the concerns raised by the MPs were understandable, given the “extraordinary speed at which the Covid-19 vaccines have been developed and brought to market”. 

“The speed achieved is the result of a strong and concerted global response to a major pandemic, rather than a compromise of safety standards,” he added.

In the meantime, HSA is reviewing vaccines developed by the United States-based firm Moderna and Sinovac from China, which have been given the green light in other countries.

Emphasising again that the standards used for assessing and approving vaccines in Singapore are based on strict international standards, Mr Gan said: “These standards are the same as those used for full vaccine evaluations, except that longer-term data from clinical trials will be evaluated only later, as the data becomes available.”

An independent expert committee appointed by the Ministry of Health (MOH) has also reviewed the data of the Pfizer-BioNTech vaccine and has agreed with HSA that the vaccine is suitable for use here by those aged 16 and older.

HSA and the committee will continue monitoring the efficacy and safety of Covid-19 vaccines in Singapore and abroad, including among pregnant women and those under the age of 16, as well as the vaccines’ long-term safety data and how long they are able to protect those inoculated against infection.

Blood donations by vaccine recipients will not be affected as coronavirus vaccines do not cause infections, Mr Gan said in response to a question by Hougang MP Dennis Tan.

NEW UK VIRUS STRAIN

On the new, potentially more transmissible virus strain seen in the United Kingdom and elsewhere in recent weeks, Mr Gan said that there is no evidence that the vaccines’ effectiveness against Covid-19 will be negatively affected by the viral mutation that created the B117 strain.

Vaccine producers, including Pfizer-BioNTech and Moderna, have given reassurances that their vaccines protect people against the new strain, he added.

On top of this, MOH is formally studying the impact of the new strain on vaccines.

Mr Gan said: “MOH will evaluate the data as it emerges and review our vaccine strategy and border measures accordingly.”

The new strain has been reported to be up to 70 per cent more infectious than previous strains.

SIDE-EFFECTS

As for the vaccines’ side-effects, Mr Gan said that HSA and the independent committee had also factored these into their evaluations, based on clinical trials and the experience from the vaccination programmes in other countries.

“As with all medications and established vaccines, there is a small risk of very rare but serious adverse events that may occur post-vaccination, including allergic reactions,” he said, referring to overseas cases of life-threatening severe allergic reactions to the Covid-19 vaccines. 

Singapore does not recommend vaccinations for those with known severe allergies.

All vaccine recipients should also be observed on site for 30 minutes after they are vaccinated, so that any severe allergic reactions such as anaphylaxis can be detected and treated promptly, Mr Gan said.

“Let me assure (members of the House) that the safety and well-being of Singaporeans is top priority in our vaccination efforts.”

Related topics

Covid-19 coronavirus vaccine Parliament Gan Kim Yong

Read more of the latest in

Advertisement

Advertisement

Stay in the know. Anytime. Anywhere.

Subscribe to get daily news updates, insights and must reads delivered straight to your inbox.

By clicking subscribe, I agree for my personal data to be used to send me TODAY newsletters, promotional offers and for research and analysis.